Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: Long-term follow-up

Diseases of the Esophagus

Volumn 23, Issue 2, 2010, Pages 160-167

  Zemanova, M ^a   Petruzelka, L ^a   Pazdro, A ^b   Kralova, D ^c   Smejkal, M ^b   Pazdrova, G ^a   Honova, H ^a  

^a Department of Oncology ^*  (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Combined modality therapy; Esophageal cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; FLUOROURACIL; PACLITAXEL; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; LONG TERM CARE; LUNG INSUFFICIENCY; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUTROPENIA; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RADIATION INDUCED EMESIS; RADIATION INJURY; RADIATION SICKNESS; RECURRENT CANCER; REMISSION; SMALL CELL CARCINOMA; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; VOMITING; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; LONGITUDINAL STUDY; MIDDLE AGED; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; ESOPHAGEAL NEOPLASMS; ESOPHAGITIS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUKOPENIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPENIA; PACLITAXEL; PROSPECTIVE STUDIES; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77953158119     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.00984.x     Document Type: Article

References (30)

1. Cancer Incidence 2004 in the Czech Republic. UZIS CR, NOR CR 2007; 68.
2. Pazdro A. Chirurgie jícnu. In: Pafko P, (ed.). Causae Mortis v chirurgii II. Praha: Grada Publishing, 2004; 63-80.
3. Walsh T N, Noonan A, Hollywood D, Kelly A, Keeling N, Hennessy T P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-7.
4. Tepper J, Krasna M J, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-92.
5. Gebski V, Burmeister B, Smithers B M et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-34.
6. Malhaire J P, Labat J P, Lozac'h P et al. Preoperative concomitant radiochemotherapy in squamous cell carcinoma of the esophagus: results of a study of 56 patients. Int J Radiat Oncol Biol Phys 1996; 34: 429-37.
7. Stahl M, Wilke H, Fink U et al. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial. J Clin Oncol 1996; 14: 829-37.
8. Urba S G, Orringer M B, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 283-5.
9. Ajani J A, Ilson D H, Daugherty K, Pazdur R, Lynch P M, Kelsen D P. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-91.
10. Schiller J H, Harrington D, Belani C P et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
11. Vaughn D J, Malkowicz S B, Zoltick B et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. J Clin Oncol 1998; 16: 255- 60.
12. Meluch A A, Hainsworth J D, Gray J R et al. Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 1999; 5: 84-91.
13. Meta-analysis Group in Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 1998; 16: 301-8.
14. Poplin E A, Benedetti J K, Estes N C et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23: 1819-25.
15. Gray J R, Hainsworth J D, Meluch A A et al. Concurrent paclitaxel/carboplatin/infusional 5-FU/radiation therapy with or without subsequent esophageal resection in patients with localized esophageal cancer: A Minnie Pearl Cancer Research Network Trial. J Clin Oncol 2005; 23 (Suppl 16S): 312s.
16. Meluch A A, Greco F A, Spigel D R et al. Long-term follow up and compilation of two trials utilizing concurrent paclitaxel/ carboplatin/infusional 5-FU/radiation therapy (RT) in patients with localized esophageal cancer involved in the Minnie Pearl Cancer Research Network (abstract). J Clin Oncol 2006; 24 (Suppl 18S): 185s.
17. Kelsey C R, Chino J P, Willett C G et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys 2007; 69: 770-6.
18. Urschel J D, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-43.
19. Fiorica F, Di Bona D, Schepis F et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004; 53: 925-30.
20. Bedenne L, Michel P, Bouché O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-8.
21. Fréchette E, Buck D A, Kaplan B J et al. Esophageal cancer: outcomes of surgery, neoadjuvant chemotherapy, and threedimension conformal radiotherapy. J Surg Oncol 2004; 87: 68-74.
22. Weiner L M, Colrusso P, Goldberg M, Dresler C, Coia L R. Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. Semin Oncol 1997; 24 (Suppl 19): 93-5.
23. Berg D, Clamon G, Riggs C Jr et al. Phase II trial of paclitaxel and carboplatin chemotherapy combined with radiation and surgery for the treatment of patients with epidermoid or adenocarcinoma of the esophagus. Proc Am Soc Clin Oncol 2000; 19: 321a.
24. Swisher S G, Ajani J A, Komaki R et al. Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2003; 57: 120-7.
25. Safran H, King T, Hesketh P et al. Phase II study of neoadjuvant paclitaxel, cisplatin and radiation followed by esophagectomy for esophageal carcinoma. Proc Am Soc Clin Oncol 1996; 15: 218.
26. Adelstein D J, Rice T W, Rybicky L A et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000; 18: 2032- 9.
27. Wright C D, Wain J C, Lynch T J et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. J Thorac Cardiovasc Surg 1997; 114: 811-6.
28. Delbaldo C, Michiels S, Syz N, Soria J C, Le Chevalier T, Pignon J P. Benefits of adding a drug to single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-84.
29. Ancona E, Ruol A, Santi S et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91: 2165-74.
30. Reynolds J V, Muldoon C, Hollywood D et al. Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg 2007; 245: 707-16.